Literature DB >> 25286799

Term delivery of a complete hydatidiform mole with a coexisting living fetus followed by successful treatment of maternal metastatic gestational trophoblastic disease.

Hsiu-Huei Peng1, Kuan-Gen Huang2, Ho-Yen Chueh1, Aizura-Syafinaz Adlan3, Shuenn-Dyn Chang1, Chyi-Long Lee1.   

Abstract

OBJECTIVE: A twin pregnancy consisting of a complete hydatidiform mole with a coexisting normal fetus is extremely rare with an incidence of 1/22,000 to 1/100,000. The incidence of preterm delivery is high and few pregnancies reach near term with a viable fetus. CASE REPORT: A 34-year-old woman presented at 20 weeks of gestation with increased levels of serum beta human chorionic gonadotropin (beta-HCG) at 4.74 multiples of the median (310277.7 mIU/mL). Ultrasonography showed a hydatidiform mole together with a normal fetus. Fetal karyotyping revealed 46XY. The serum beta-HCG levels were followed up throughout the remainder of the pregnancy. A male infant weighting 2260 g and the molar tissue were delivered at 37 weeks of gestation. The karyotype of the molar tissue showed 46XX and the histopathological report confirmed our diagnosis. At 4 months postpartum, metastatic gestational trophoblastic disease of the lung was diagnosed in the mother by a computed tomography scan due to increased beta-HCG levels. The patient received three unsuccessful cycles of methotrexate and folinate. Another four cycles of chemotherapy consisting of etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA-CO) were initiated and the beta-HCG levels returned to normal. There was no evidence of recurrence in the subsequent 5 years of regular follow up.
CONCLUSION: A pregnancy with a complete hydatidiform mole and a living cotwin can be a serious threat to the health of both the mother and the fetus. Early diagnosis depends on a combination of detecting an unusually high level of serum beta-HCG and ultrasound examination. We suggest that continuation of the pregnancy may be an acceptable option and that the pregnancy may continue until term if a normal fetal anatomy is assured and maternal complications are under control. Patients require careful postpartum follow up and any recurrent disease should be managed aggressively.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  EMA-CO; metastatic gestational trophoblastic disease; twin pregnancy with one complete hydatidiform mole

Mesh:

Year:  2014        PMID: 25286799     DOI: 10.1016/j.tjog.2013.02.005

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  6 in total

1.  Partial hydatidiform mole pregnancy ended in full-term delivery of a normal infant: a case presentation.

Authors:  Qing-Hua Qu; Yi Lin; Xue Feng; Li-Juan Hao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Ultrasound and MRI Findings of Twin Pregnancies with Complete Hydatidiform Mole and Coexisting Normal Fetus: Two Case Reports.

Authors:  Hitomi Imafuku; Yoshiya Miyahara; Yasuhiko Ebina; Hideto Yamada
Journal:  Kobe J Med Sci       Date:  2018-05-28

3.  Partial Hydatidiform Mole and Coexistent Live Fetus: A Case Report and Review of the Literature.

Authors:  Chengying Zeng; Yanbi Chen; Lijuan Zhao; Bo Wan
Journal:  Open Med (Wars)       Date:  2019-11-10

4.  Molar pregnancy with a coexisting living fetus: a case series.

Authors:  Reda Hemida; Eman Khashaba; Khaled Zalata
Journal:  BMC Pregnancy Childbirth       Date:  2022-09-03       Impact factor: 3.105

5.  Twin pregnancy with metastatic complete molar pregnancy and coexisting live fetus.

Authors:  Devang Odedra; Kelsey MacEachern; Lorraine Elit; Sarab Mohamed; Elizabeth McCready; Bryon DeFrance; Yongdong Wang
Journal:  Radiol Case Rep       Date:  2019-12-18

Review 6.  A challenging case of twin pregnancy with complete hydatidiform mole and co-existing normal live fetus - A case report and review of the literature.

Authors:  L B Lipi; L Philp; A K Goodman
Journal:  Gynecol Oncol Rep       Date:  2019-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.